These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19754389)

  • 1. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.
    Tavridou A; Manolopoulos VG
    Curr Pharm Des; 2009; 15(27):3167-78. PubMed ID: 19754389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.
    Tavridou A; Kaklamanis L; Megaritis G; Kourounakis AP; Papalois A; Roukounas D; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG
    Eur J Pharmacol; 2006 Mar; 535(1-3):34-42. PubMed ID: 16545796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit.
    Tavridou A; Kaklamanis L; Papalois A; Kourounakis AP; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG
    J Pharmacol Exp Ther; 2007 Dec; 323(3):794-804. PubMed ID: 17804677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells.
    Tavridou A; Megaritis G; Kourounakis AP; Charalambous A; Manolopoulos VG
    Endothelium; 2007; 14(4-5):239-43. PubMed ID: 17922341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit.
    Tavridou A; Kaklamanis L; Papalois A; Kourounakis AP; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):573-80. PubMed ID: 18520953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo.
    Tavridou A; Manolopoulos VG
    Eur J Pharmacol; 2004 Nov; 505(1-3):213-21. PubMed ID: 15556155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents.
    Kourounakis AP; Katselou MG; Matralis AN; Ladopoulou EM; Bavavea E
    Curr Med Chem; 2011; 18(29):4418-39. PubMed ID: 21864285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
    Katselou MG; Matralis AN; Kourounakis AP
    Eur J Med Chem; 2017 Sep; 138():748-760. PubMed ID: 28728107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
    Charlton-Menys V; Durrington PN
    Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of more potent squalene synthase inhibitors with multiple activities.
    Kourounakis AP; Matralis AN; Nikitakis A
    Bioorg Med Chem; 2010 Nov; 18(21):7402-12. PubMed ID: 20888243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity.
    Kourounakis AP; Charitos C; Rekka EA; Kourounakis PN
    J Med Chem; 2008 Sep; 51(18):5861-5. PubMed ID: 18754614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
    Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H
    Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.
    Shiomi M; Yamada S; Amano Y; Nishimoto T; Ito T
    Br J Pharmacol; 2008 Jul; 154(5):949-57. PubMed ID: 18587443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiomorpholine Derivatives with Hypolipidemic and Antioxidant Activity.
    Tooulia KK; Theodosis-Nobelos P; Rekka EA
    Arch Pharm (Weinheim); 2015 Sep; 348(9):629-34. PubMed ID: 26191791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity.
    Matralis AN; Kourounakis AP
    J Med Chem; 2014 Mar; 57(6):2568-81. PubMed ID: 24568631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.
    Kerr AG; Tam LCS; Hale AB; Cioroch M; Douglas G; Agkatsev S; Hibbitt O; Mason J; Holt-Martyn J; Bataille CJR; Wynne GM; Channon KM; Russell AJ; Wade-Martins R
    J Pharmacol Exp Ther; 2017 Jun; 361(3):417-428. PubMed ID: 28360334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New lipid-lowering agents acting on LDL receptors.
    Scharnagl H; März W
    Curr Top Med Chem; 2005; 5(3):233-42. PubMed ID: 15857307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
    Amano Y; Nishimoto T; Tozawa Ri; Ishikawa E; Imura Y; Sugiyama Y
    Eur J Pharmacol; 2003 Apr; 466(1-2):155-61. PubMed ID: 12679152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a new squalene synthase inhibitor on an ApoE
    Matralis AN; Kaklamanis L; Perrea D; Kourounakis AP
    Bioorg Med Chem; 2023 Jul; 90():117378. PubMed ID: 37336084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis.
    Matralis AN; Bavavea EI; Incerpi S; Pedersen JZ; Kourounakis AP
    Curr Med Chem; 2017; 24(12):1214-1227. PubMed ID: 27528055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.